Drug intelligence / Profile preview

Trisequens Forte

Development stage: Unknown
Lead developer: Novo Nordisk
Modality: Small Molecules
Administration: Oral

Overview

Trisequens Forte is a continuous sequential hormone replacement therapy (HRT) product containing estradiol and norethisterone acetate. It is used to treat symptoms of estrogen deficiency associated with menopause, such as hot flushes, night sweats, and to prevent osteoporosis in postmenopausal women. The medication delivers higher doses of hormones compared to regular Trisequens, with a 28-day cycle consisting of three different tablet types: 12 days of estrogen-only therapy (yellow tablets), followed by 10 days of combined estrogen/progestagen therapy (white tablets), and 6 days of lower-dose estrogen therapy (red tablets).

Brand names: Trisequens Forte

Targets

PR (Progesterone receptor)ER (Estrogen receptor)

Beyond the preview

Go deeper on Trisequens Forte.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trisequens Forte.

Explore the full profile